Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Diagnosis and Management of Neuromyelitis Optica Spectrum Disorder (Nmosd) in Iran: A Consensus Guideline and Recommendations Publisher Pubmed



Sahraian MA1, 2 ; Moghadasi AN1 ; Azimi AR1, 2 ; Asgari N3 ; Akhoundi FH4 ; Abolfazli R5 ; Alaie S6 ; Ashtari F7, 17 ; Ayromlou H8 ; Baghbanian SM9 ; Moghadam NB10 ; Fatehi F2, 11 ; Foroughipour M12 ; Langroodi HG13 Show All Authors
Authors
  1. Sahraian MA1, 2
  2. Moghadasi AN1
  3. Azimi AR1, 2
  4. Asgari N3
  5. Akhoundi FH4
  6. Abolfazli R5
  7. Alaie S6
  8. Ashtari F7, 17
  9. Ayromlou H8
  10. Baghbanian SM9
  11. Moghadam NB10
  12. Fatehi F2, 11
  13. Foroughipour M12
  14. Langroodi HG13
  15. Majdinasab N14
  16. Nickseresht A15
  17. Nourian A16
  18. Shaygannejad V17
  19. Torabi HR6
Show Affiliations
Authors Affiliations
  1. 1. MS Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Iran
  2. 2. Iranian Center for Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Iran
  3. 3. Institutes of Regional Health Research and Molecular Medicine, University of Southern Denmark, Denmark
  4. 4. Department of Neurology, Firozgar Hospital, Iran University of Medical Sciences, Iran
  5. 5. Department of Neurology, Amiralam Hospital, Tehran University of Medical Sciences, Iran
  6. 6. Scientific Committee, Iranian MS Society, Iran
  7. 7. Department of Neurology, Kashani Hospital, Isfahan University of Medical Sciences, Iran
  8. 8. Department of Neurology, Faculty of Medicine, Tabriz University of Medical Sciences, Iran
  9. 9. Department of Neurology, Booalisina Hospital, Mazandaran University of Medical Sciences, Iran
  10. 10. Department of Neurology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Iran
  11. 11. Department of Neurology, Shariati Hospital, Tehran University of Medical Sciences, Iran
  12. 12. Department of Neurology, Faculty of Medicine, Mashhad University of Medical Sciences, Iran
  13. 13. Department of Internal medicine and Neurology, Ghaem Int. Hospital, Rasht, Iran
  14. 14. Department of Neurology, Golestan Hospital, Ahwaz University of Medical Sciences, Iran
  15. 15. Department of Neurology, Namazi Hospital, Shiraz University of Medical Sciences, Iran
  16. 16. Islamic Azad University, Faculty of Medicine, Khorasan Razavi Branch, Iran
  17. 17. Isfahan neurosciences research center, Alzahra Hospital, Department of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Multiple Sclerosis and Related Disorders Published:2017


Abstract

Neuromyelitis Optica Spectrum Disorder (NMOSD) is a relapsing neuro inflammatory disease of the central nervous system that typically presents with optic neuritis or myelitis and may cause severe disability. The diagnostic criteria have been updated and several immunosuppressive agents have been demonstrated to prevent acute exacerbations. As the disease rarely develops in a progressive course, management of acute attacks and proper prevention of exacerbations may change the long term out-come and prevent future disability. Consensus recommendations and guidelines will help the physicians to improve their practice and unify the treatment approaches in different communities. In order to develop a national consensus and recommendations for the diagnosis and management of NMOSD in Iran, a group of neurologists with long term experience in management of NMOSD were gathered to develop this consensus based on available national and international data. The primary draft was prepared and discussed to suggest the most appropriate treatment for these patients. We propose strategies for early diagnosis and treatment for prevention of relapses and minimizing consequences of attacks as a primary therapeutic goal. Attacks are currently treated with intravenous corticosteroids and, in refractory cases, with plasma exchange. All participants agreed on preventive treatment with currently available immunosuppressive agents such as azothioprin, rituximab and mycofenolate mofetil based on previous positive data in NMOSD in order to reduce attack frequency. The current consensus reviews the previous data and provides the clinicians with practical recommendations and advices for the diagnosis and management of NMOSD based on scientific data and clinical experience. © 2017 Elsevier B.V.
Other Related Docs
10. Whole Spinal Transverse Myelitis in Neuromyelitis Optica Spectrum Disorder, Multiple Sclerosis and Related Disorders (2024)
25. Retinal Changes in Double-Antibody Seronegative Neuromyelitis Optica Spectrum Disorders, Neurology: Neuroimmunology and NeuroInflammation (2024)
27. Frequency of Diencephalic Syndrome in Nmosd, Acta Neurologica Belgica (2022)
30. Vitamin D Level in Iranian Patients With Neuromyelitis Optica, Journal of Isfahan Medical School (2021)
35. Retinal Optical Coherence Tomography in Neuromyelitis Optica, Neurology: Neuroimmunology and NeuroInflammation (2021)
43. Diagnosis and Classification of Optic Neuritis, The Lancet Neurology (2022)